Contribution of Anti-platelet Antibodies Identified With Monoclonal Antibody Immobilization of Platelet Antigens Assay (MAIPA) to Confirm Autoimmune Nature of Thrombocytopenia at Diagnosis

What this Trial Is About

Immune thrombocytopenia (ITP) is an autoimmune disorder where the diagnosis and prognosis do not typically involve measuring antiplatelet antibodies. Unlike other autoimmune diseases, these antibodies are not standard for diagnosis. This trial aims to evaluate the role of anti-platelet antibodies detected using the Monoclonal Antibody Immobilization of Platelet Antigens (MAIPA) assay in confirming the autoimmune nature of thrombocytopenia at diagnosis, addressing a gap in current clinical knowledge. Participants will undergo blood sampling for various tests including measurement of thrombopoietin and both free and platelet-bound anti-platelet antibodies through the MAIPA assay. The amount of blood drawn depends on platelet counts, ranging from 14 ml to 49 ml for specific isolations. This is an interventional study where these biological samples will be analyzed to assess the presence of antibodies and their diagnostic value. During the study, participants will be monitored for the presence of autoimmune thrombocytopenia and chronic ITP status over 12 months. Blood tests will be conducted at baseline and after 12 months to measure serum thrombopoietin and antibody presence. The main outcome is the percentage of patients diagnosed with autoimmune thrombocytopenia based on antibody detection at 12 months, alongside secondary outcomes including chronic ITP rates and thrombopoietin levels.

Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis